0102030405
Lapatinib CAS No. 231277-92-2 Antineoplastic Pharmaceutical Raw Material
02
introduce
introduce
Lapatinib is a potent oral dual tyrosine kinase inhibitor (TKI) and core antineoplastic pharmaceutical API. It specifically targets EGFR (ErbB1) and HER2 (ErbB2) receptors, blocking tumor cell proliferation and survival signals.
Our products comply with strict international standards to ensure high purity, stable efficacy, and reliable supply for clinical use and biomedical research.
02
Physical and chemical properties
Lapatinib exhibits key physical and chemical characteristics supporting its pharmaceutical and research applications, as follows:
- Melting Point: 144-147 °C
- Boiling Point: 750.7±60.0 °C
- Density: 1.4±0.1 g/cm³
- Solubility: Soluble in DMSO (up to 200 mg/mL)
- Stability: Stable for 2 years as supplied; DMSO solutions stable at -20 °C for up to 1 month
- Melting Point: 144-147 °C
- Boiling Point: 750.7±60.0 °C
- Density: 1.4±0.1 g/cm³
- Solubility: Soluble in DMSO (up to 200 mg/mL)
- Stability: Stable for 2 years as supplied; DMSO solutions stable at -20 °C for up to 1 month
1. Potent Dual-Target Inhibition for Anti-Tumor Effect
As a reversible small-molecule tyrosine kinase inhibitor, it precisely inhibits two key targets (EGFR and HER2) simultaneously, double-blocking the proliferation signal pathways of tumor cells, with a far better anti-tumor effect than single-target tyrosine kinase inhibitors (e.g., erlotinib, gefitinib).
As a reversible small-molecule tyrosine kinase inhibitor, it precisely inhibits two key targets (EGFR and HER2) simultaneously, double-blocking the proliferation signal pathways of tumor cells, with a far better anti-tumor effect than single-target tyrosine kinase inhibitors (e.g., erlotinib, gefitinib).
2. Applicable to Resistant Scenarios and Filling Clinical Gaps
It has a definite inhibitory effect on trastuzumab-resistant HER2-positive breast cancer cell lines, solving the problem of drug resistance in some patients to traditional HER2 monoclonal antibody targeted drugs, while trastuzumab has no therapeutic effect on such resistant cells.
It has a definite inhibitory effect on trastuzumab-resistant HER2-positive breast cancer cell lines, solving the problem of drug resistance in some patients to traditional HER2 monoclonal antibody targeted drugs, while trastuzumab has no therapeutic effect on such resistant cells.
3. High Target Selectivity and Better Medication Safety
It has strong inhibitory activity against EGFR and HER2, with over 300-fold selectivity for these two targets over other kinases. Compared with broad-spectrum anti-tumor drugs, it causes less damage to normal human cells. Meanwhile, it acts only on intracellular target pathways with a mechanism different from trastuzumab, making cross-resistance less likely to occur.4. Significant Efficacy in Combination Therapy, Superior to Monotherapy
When combined with capecitabine for advanced breast cancer, its efficacy rate and clinical benefit rate are much higher than lapatinib monotherapy. The efficacy rate of monotherapy as first-line treatment is only 12~24%, while the combination therapy can reach an efficacy rate of 26~33% and a maximum clinical benefit rate of 71.3%, which is a clinically preferred combination therapy regimen.
Its core application is tumor targeted therapy, mainly for breast cancer treatment, and it also has certain research and clinical expansion application value. The specific scenarios include:
1. Core Indication
Combined with capecitabine, it is used to treat patients with HER2 (ErbB2)-overexpressing advanced or metastatic breast cancer, especially those who have previously received anthracycline, taxane chemotherapy and trastuzumab targeted therapy.
2. Treatment of Resistant Breast Cancer
It is used for patients with trastuzumab-acquired resistant HER2-positive breast cancer, serving as an important second-line treatment option for such resistant patients.
3. Expanded Application in Tumor Treatment
It can enhance the therapeutic efficacy of cisplatin on bladder cancer cells with high expression of EGFR and HER2, providing a potential combination medication direction for the treatment of such urinary system tumors.
4. Research Application
It can be used as a tool drug for tyrosine kinase inhibitor and anti-tumor research, applied in biomedical research such as the mechanism of targeted therapy and target action research of breast cancer.
Combined with capecitabine, it is used to treat patients with HER2 (ErbB2)-overexpressing advanced or metastatic breast cancer, especially those who have previously received anthracycline, taxane chemotherapy and trastuzumab targeted therapy.
2. Treatment of Resistant Breast Cancer
It is used for patients with trastuzumab-acquired resistant HER2-positive breast cancer, serving as an important second-line treatment option for such resistant patients.
3. Expanded Application in Tumor Treatment
It can enhance the therapeutic efficacy of cisplatin on bladder cancer cells with high expression of EGFR and HER2, providing a potential combination medication direction for the treatment of such urinary system tumors.
4. Research Application
It can be used as a tool drug for tyrosine kinase inhibitor and anti-tumor research, applied in biomedical research such as the mechanism of targeted therapy and target action research of breast cancer.
We implement strict full-process quality control, with each batch of Lapatinib undergoing rigorous testing of key indicators including purity, solubility, stability, enantiomeric excess, and biological activity to meet standards.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support.
As a classic dual EGFR/HER2 tyrosine kinase inhibitor, Lapatinib has become a cornerstone in treating advanced HER2-positive breast cancer, especially for patients with prior therapy resistance. With its targeted mechanism, proven efficacy, exceptional quality, and reliable supply capacity, we are committed to providing high-quality Lapatinib API and professional services for global pharmaceutical companies, research institutions, and clinical applications.
Choose our Lapatinib to meet your needs in pharmaceutical formulation, oncology research, and clinical treatment. Contact us for more product details and cooperation support.
Choose our Lapatinib to meet your needs in pharmaceutical formulation, oncology research, and clinical treatment. Contact us for more product details and cooperation support.